Evaluation of the Safety of Taking Brexpiprazole During the Lactation Period
This study suggests that BPZ monotherapy (1-2 mg/day) during lactation does not lead to withdrawal symptoms or serious adverse events in newborns or infants within the first month postpartum. This initial evidence may help inform breastfeeding decisions among mothers receiving BPZ monotherapy.
Authors
- Aoi Noda
- Riko Iwabuchi
- Shinichi Sato (ORCID: https://orcid.org/0000-0002-6308-1034)
- Takushi Hanita (ORCID: https://orcid.org/0000-0001-5855-0222)
- Natsuko Kobayashi
- Masatoshi Saito
- Nariyasu Mano (ORCID: https://orcid.org/0000-0003-1679-9024)
- Nao Okabe
- Hasumi Tomita (ORCID: https://orcid.org/0000-0003-3942-8592)
- Akari Fukuda (ORCID: https://orcid.org/0000-0003-1284-1301)
- Kei Morishita (ORCID: https://orcid.org/0000-0002-0250-2800)
- Saya Kikuchi
- Noriyuki Iwama
- Hiroaki Tomita
- Erika Kimura
- Chihiro Iwasaki
- Gen Oyanagi
- Taku Obara
- Miyu Okubo
Institutions
- Tohoku University Hospital (JP)
Publication Details
- Journal
- Breastfeeding Medicine
- Published
- 2026-02-06
- DOI
- https://doi.org/10.1177/15568253251408037
- Primary Topic
- Breastfeeding Practices and Influences
- Type
- article
- Field-Weighted Citation Impact
- 0.00